Core Viewpoint - The company announced that its self-developed VAV1 molecular glue degrader ICP-538 has been approved by the National Medical Products Administration (NMPA) for clinical research, marking it as the first in China and the second globally to enter clinical trials [1] Group 1: Product Development - ICP-538 is a novel oral, highly efficient, and selectively targeted VAV1-specific molecular glue degrader [1] - VAV1 is a key protein downstream of T cell and B cell receptors, which is crucial for developing treatments for various difficult-to-treat autoimmune diseases [1] Group 2: Target Indications - The drug is aimed at treating multiple challenging autoimmune diseases, including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) [1]